{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jain S"],"funding":["Clinical Translational Science Center","Cure, New York Community Trust, Cancer Research and Treatment Fund","NCATS NIH HHS","NCRR NIH HHS","Berman Fund","Anne Moore Breast Cancer Research Fund, Stephen and Madeline Anbinder Foundation, Rozaliya Kosmandel Research Fund"],"pagination":["1491-8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3707432"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(6)"],"pubmed_abstract":["<h4>Background</h4>Bone marrow-derived endothelial progenitor cells (EPCs) are critical for metastatic progression. This study explores the effect of tetrathiomolybdate (TM), an anti-angiogenic copper chelator, on EPCs in patients at high risk for breast cancer recurrence.<h4>Patients and methods</h4>This phase 2 study enrolled breast cancer patients with stage 3 and stage 4 without evidence of disease (NED), and stage 2 if triple-negative. TM 100 mg orally was administered to maintain ceruloplasmin <17 mg/dl for 2 years or until relapse. The primary end point was change in EPCs.<h4>Results</h4>Forty patients (28 stage 2/3, 12 stage 4 NED) were enrolled. Seventy-five percent patients achieved the copper depletion target by 1 month. Ninety-one percent of triple-negative patients copper-depl"],"journal":["Annals of oncology : official journal of the European Society for Medical Oncology"],"pubmed_title":["Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse."],"pmcid":["PMC3707432"],"funding_grant_id":["UL1 TR000457","UL1-RR024996"],"pubmed_authors":["Kornhauser N","Jain S","Warren JD","Cobham MV","Schneider S","Vahdat LT","Chuang E","Lam C","Donovan D","Cigler T","Zelkowitz R","Lane ME","Mathijsen Greenwood C","Mittal V","Rafii S","Moore A","Cohen J","Ward MM","Hurtado Rua SM","Benkert S"],"additional_accession":[]},"is_claimable":false,"name":"Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse.","description":"<h4>Background</h4>Bone marrow-derived endothelial progenitor cells (EPCs) are critical for metastatic progression. This study explores the effect of tetrathiomolybdate (TM), an anti-angiogenic copper chelator, on EPCs in patients at high risk for breast cancer recurrence.<h4>Patients and methods</h4>This phase 2 study enrolled breast cancer patients with stage 3 and stage 4 without evidence of disease (NED), and stage 2 if triple-negative. TM 100 mg orally was administered to maintain ceruloplasmin <17 mg/dl for 2 years or until relapse. The primary end point was change in EPCs.<h4>Results</h4>Forty patients (28 stage 2/3, 12 stage 4 NED) were enrolled. Seventy-five percent patients achieved the copper depletion target by 1 month. Ninety-one percent of triple-negative patients copper-depl","dates":{"release":"2013-01-01T00:00:00Z","publication":"2013 Jun","modification":"2026-05-30T10:38:20.537Z","creation":"2026-04-08T07:01:19.597Z"},"accession":"S-EPMC3707432","cross_references":{"pubmed":["23406736"],"doi":["10.1093/annonc/mds654"]}}